Indeed, treatment of MYC-driven B-cell lymphoma with CX-5461, via inhibition of rDNA transcription, in combination with Phosphoinositide 3-kinase (PI3K), AKT and mammalian target of rapamycin complex (mTORC) inhibitors, disrupting the recruitment of ribosomes to the mRNA, lead to increased tumour cell death and prolonged survival [122]. Here, MYC is linked to neoplasm.